Sirolimus is under clinical development by Biodexa Pharmaceuticals and currently in Phase II for Prostate Cancer. According to GlobalData, Phase II drugs for Prostate Cancer have a 23% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Sirolimus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Sirolimus overview

Sirolimus (rapamycin) is under development for the treatment of non-muscle Invasive bladder cancer, prostate cancer and familial adenomatous polyposis. It is administered through oral route. The drug candidate is an encapsulated rapamycin consisting of sub-micron rapamycin particles incorporated into poly (methyl methacrylate) polymer. It was under development for the treatment of Alzheimer's disease, ageing and acute respiratory distress syndrome (RAPA-CARDS) due to Coronavirus disease 2019 (COVID-19).

Biodexa Pharmaceuticals overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Biodexa Pharmaceuticals, formerly Midatech Pharma Plc, is a clinical-stage biopharmaceutical company. It develops a pipeline of products aimed at primary and metastatic cancers of the brain. The company’s pipeline products include MTX110, a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. and MTD217. Its product pipeline treats diffuse midline glioma, glioblastoma, medulloblastoma and leptomeningeal disease. The company conducts research and development programs in the areas of oncology, autoimmune diseases, octreotide and glioblastoma. Biodexa Pharmaceuticals is headquartered in Cardiff, Wales, the UK.

For a complete picture of Sirolimus’s drug-specific PTSR and LoA scores, buy the report here.